Table 4 Summary of studies detecting IgG autoantibody to FcεR1α in subjects with CSU
| Reference (author, year) | Region | Definition of CSU in weeks | Number of CSU patients undergoing testing | Number of healthy controls undergoing testing | % prevalence of IgG autoantibody to FcεR1α in study group | Functional assay (F) or non-functional assay (N) | % prevalence of IgG autoantibody to FcεR1α in control group | Number of antihistamine (AH) and/or systemic corticosteroid (SC)-free days |
|---|---|---|---|---|---|---|---|---|
| Hide, 1993 [88] | England | > 8 | 26 + ASST | 10 | 46.1 | F | 0 | 2 (AH) |
| Fiebiger, 1995 [11] | Austria | > 8 | 32 | 15 | 37 | N | 0 | Not stated |
| Zweiman, 1996 [89] | United States | – | 70 | 20 | 30 | F | 15 | Not stated |
| Ferrer 1998 [10] | United States | > 12 | 53 | 24 | 64 | N | 0 | 2 (AH) |
| Fiebiger, 1998 [90] | Austria | > 8 | 281 | 41 | 38 | N | – | Not stated |
| Zuberbier, 2000 [91] | Austria | > 6 | 48 | 5 | 35 | N | 0 | Not stated |
| Sabroe, 2002 [92] | England | > 6 | 78 | 39 |
26 15 |
F N | 0 | 3 (AH), 28 (SC) |
| Hidvegi, 2003 [93] | Hungary | > 6 | 50 | 9 | 34 | N | 0 | 3 (AH), 28 (SC) |
| Eckman, 2008 [94] | United States | > 6 | 73 | 23 | 59 | N | 57 | Not stated |
| Lee, 2014 [95] | Taiwan | > 6 | 40 (20 + ASST) (20 − ASST) | 20 | 47.5 (70) (25) | N | 5 | Not stated |
| Ulambayar, 2017 [96] | Taiwan | > 6 | 125 (64 + ASST) (61 − ASST) | 64 | 24.8 (32.8) (16.4) | N | 3.1 | 5 (AH) |
| Baioumy, 2018 [97] | Egypt | > 8 | 40 (18 + ASST) (22 − ASST) | 40 | 52.5 (83.3) (27.3) | N | 2.5 | 5 (AH) |
| Schoepke, 2019 [98] | Multinational | > 6 | 182 (107 + ASST) | 0 | 58 | N | – | 3 (AH), 28 (SC) |
| Asero, 2020 [99] | Italy | > 6 | 20 | 20 | 50 | N | – | Not stated |